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SignalingRas isoforms are membrane bound proteins that differentially localize to the plasma membrane and subcel-
lular compartments within the cell. Whilst the cell surface is the main site for Ras activity the extent to which
intracellular pools contribute to Ras function is debated. We have generated Ras chimeras targeting Ras to the
ER, Golgi, mitochondria and endosomes to compare the capacity of each of these locations to support activity
equivalent to normal Ras function. We ﬁnd that all locations are capable of regulating the MAP kinase and Akt
pathways. Furthermore, whilst endomembranous Ras pools show location-speciﬁc competence to support
proliferation and transformation, Golgi-Ras is as potent as N-Ras.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Ras operates as a molecular switch near the top of many signaling
cascades and regulates diverse cellular functions including prolifera-
tion, differentiation, migration, apoptosis and senescence. Despite a
high degree of sequence homology and ubiquitous expression proﬁles
the Ras isoforms H-Ras, N-Ras, and K-Ras generate different signal
outputs. These include distinct contributions to embryonic development,
cancer development, cellular homeostasis anddifferential coupling to ca-
nonical effector pathways [1–3]. Differences in relative compartmentali-
zation of Ras isoforms bothwithin and between organelles are suggested
to be responsible for these signaling differences [4].
The 25/26 amino acid C-terminal hypervariable domain (HVR) of
Ras is post-translationally modiﬁed to facilitate membrane binding
and correct trafﬁcking [5]. Each isoform has a distinct set of modiﬁca-
tions and targetingmotifs that result in overlapping but distinctive lo-
calizations. Whilst the plasma membrane is the main site of action for
Ras proteins, association with the plasmamembrane is highly dynamic
and regulated by the activation state of the Ras protein [4]. Consequent-
ly, endomembranous pools of each isoform have been characterized
that include the endosome, mitochondria and the ER/Golgi complex
[6–13]. Endocytic and cytosolic transfer of activated Ras and in situ acti-
vation of Ras on endomembranous platforms have all been observednc. Open access under CC BY-NC-ND li[14–17]. The presence of activated Ras on intracellular organelles
suggests a functional role that is supported by data from T cells where
opposing effects on immunological selection are produced by Ras acti-
vation on the cell surface versus the Golgi [18].
Despite these results there is still relatively little insight into the
ability of endomembranous Ras to mediate canonical Ras functions.
Dissecting the role of speciﬁc compartments in regulating Ras function
is complicated by the pools of endogenous Ras still present on other or-
ganelles. One strategy to investigate this has involved ectopic expression
of a constitutively active Ras chimera where mutations or motifs have
been introduced into the N- or C-terminus to direct the Ras protein to
the required subcellular compartment. This allows the potential of subcel-
lular platforms to sustain particular signaling pathways to be character-
ized. A recent study using this approach found that a plasma membrane
restricted Ras protein was unable to efﬁciently induce NIH3T3 cell trans-
formation in comparisonwith Ras that could also access endomembranes
[19]. Crespo and colleagues have conducted the most systematic attempt
to characterize organellar Ras signaling and found that Golgi-Ras is unable
to support Ras-induced NIH3T3 cells transformation or proliferation [20].
This was associated with an inability of Golgi-Ras to activate the ERK and
Akt pathways. In contrast, endoplasmic reticulum (ER)-restricted Ras and
Ras occupying distinct plasma membrane microdomains could equiva-
lently sustain normal Ras signaling and function.
In this study we have extended these previous observations by
using an isogenic NIH3T3 cell line approach to compare the signaling
and function of Ras proteins targeted to all organelles where Ras has
been detected. We ﬁnd that all locations are able to modulate signaling
via theRaf andPtdIns-3 kinase (PI3K) pathways. All subcellular locations
are also able to promote proliferation and transformation to varying
degrees. In contrast to previous data we ﬁnd that Golgi-Ras performscense. 
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capacity of subcellular organelles to support basic Ras functions albeit
with important location-speciﬁc differences.
2. Results and discussion
Early work to compare location-speciﬁc Ras signaling focused on
the role of the ER/Golgi and plasma membrane signaling domains in
modulating Ras outputs [21,22,7,20]. Manipulating the C-terminal
HVR and adding speciﬁc organelle targeting motifs enabled redirection
or restriction of constitutively active Ras proteins to speciﬁc areas of
the cell and measurement of cell signaling outputs. Since these inﬂuen-
tial studies, it has become increasingly clear that activated Ras isoforms
are able to access the endocytic network and mitochondria from where
they are proposed tomodulate proliferative and pro-apoptotic signaling
respectively [23,24,9,10,13,25]. What is not clear is the relative potency
of these locations in supporting Ras function.
To address this, we constructed a series of targeted Ras chimeras
encoding GFP at the N-terminus and an organelle-targeting motif at
the C-terminus to replace the conventional targeting encoded within
the Ras HVR (Fig. 1A). Whilst N-Ras was used as the donor for the
N-terminal Ras G-domain, these constructs can be described as generic
Ras molecules since Ras isoform-speciﬁcity is encoded within the HVR
that has been replaced. Previous work to target Ras to distinct subcellu-
lar locations has typically involved fusing a membrane targeting signal
to the N-terminus of H-Ras. For ER/Golgi-Ras this incorporated residues
1–66 of M1 avian infectious bronchitis virus and for Golgi-Ras a mutant
(N193D) KDEL receptor with impaired ability to recycle to the ER was
used [20]. With higher levels of expression of KDELr-Ras, clear ER label-
ing can be observed (data not shown). Therefore to reduce this and toFig. 1. Tethering Ras to different subcellular locations. (A) Schematic proﬁle of all constructs
constructs in HeLa cells. Ras proteins were visualized by anti-GFP (green) and co-locali
endosomal location and anti-TOM20 (red) to conﬁrm mitochondrial location.standardize the topology of the ﬂuorescent reporter and membrane
targeting motifs amongst all of our constructs, we generated a new
Golgi-Ras using the Golgi-targeting domain of GM130 [26]. Almost
complete co-localisation with the Golgi resident protein GRASP55 is
observed (Fig. 1B). Previous work from our lab had also generated an
alternative ER/Golgi-Ras by modifying the HVR of N-Ras [27]. Speciﬁc
localization to the ER/Golgi can be seen including peripheral reticular,
nuclear envelope and peri-nuclear Golgi cisternal stack labeling (Fig. 1B).
In addition to these constructs that reproduce targeting to locations
compared in previous studies we also generated mitochondrial and
endomembrane-speciﬁc Ras. Addition of the C-terminal 36 amino acid
transmembrane and basic domain frommitochondrial outermembrane
protein 25 (OMP25) [28] resulted in exclusive mitochondrial Ras local-
ization (Fig. 1B). For endosomal/endomembrane targeting we used
tandem FYVE domains from FENS1 to promote enrichment on the
early endocytic network via PtdIns-3P interactions [29]. Whilst this
is the least speciﬁcally localized of our organellar Ras proteins, clear
co-localisation with the early endosomal marker EEA1 is observed
(Fig. 1B). N-Ras is used as a positive control for normal Ras signaling.
This was chosen due to it being the source of the G domain in our organ-
elle Ras constructs and because it displays the most endomembranous
distribution of the three Ras isoforms [2], with peri-nuclear ER/Golgi la-
beling being clearly evident (Fig. 1B).
NIH3T3 cells lines stably expressing wild type and constitutively
active version of each compartmental-Ras were generated using FLP
recombinase technology [30]. A single integration site is present within
the Flp-In NIH3T3 cell genome for receipt of the organellar Ras DNA.
This reduces the opportunity for non-speciﬁc effects due to random inte-
gration of DNA associated with conventional stable cell line generation.
Expression amongst the wild type and active organellar Ras constructsgenerated. (B) Confocal images showing subcellular locations of the transient expressed
zed with anti-Grasp55 (red) to conﬁrm Golgi tethering, anti-EEA1 (red) to conﬁrm
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of expression as GFP-N-Ras (Fig. 2A). Analysis of signaling via canonical
Ras effector pathways revealed that in the absence of serum, N-Ras,Fig. 2. Expression levels of the targeted Ras proteins, their ability to engage effectors and bi
using 20 μg lysates from the NIH3T3 FLP-IN clones. Anti-tubulin was used as loading control.
vation, 20 μg lysates from NIH3T3 FLP-IN cells stably expressing the indicated constructs w
using anti-pMEK, anti-pAKT and anti-tubulin respectively. (C) Ras activation was assaye
Bound protein was detected by immunoblot using anti-GFP antibody. This ﬁgure shows repGolgi-Ras and ER/Golgi-Ras each exhibited potent MEK activation in
the presence of activated versus wild type Ras (Fig. 2B). In contrast,
mito-Ras and endo-Ras showed little to no difference inMEK activationnd GST-RBD. (A) Ras protein expression was determined by anti-GFP-immunoblotting
(B) Ras effector activation at different compartments was analyzed. Following 6 h star-
ere immunoblotted to determine pAKT, pMEK and the loading control tubulin levels
d via pull-down GST–RBD K85A fusion protein linked to glutathione–Sepharose 4B.
resentative blots from three biological repeats.
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cells. An inability of endo-Ras to activate the MAPK pathway is con-
sistent with previous data that showed that ubiquitination of Ras
resulting in enhanced Ras endocytosis attenuated Ras-dependent
ERK activation [10]. We conﬁrmed that the G12V mutant Ras proteins
were active in each location albeit to different extents; endo-Ras activa-
tion was below the limit of detection (Fig. 2C). Similarly to N-Ras,
Golgi-Ras and ER/Golgi-Ras show residual activation associated with
the wild type constructs when grown in standard cell culture media
that includes FBS.
Our results with Golgi-Ras superﬁcially appear to be in contrast to
the study of Matallanas et al. (2006) that showed an impaired ability
of Golgi-Ras to activate ERK and Akt. However in this previous study
only activated (G12V) mutants were compared whereas we also in-
clude the wild type versions too. Therefore whilst Golgi-Ras shows a
clear enhancement of MEK activation when constitutively active,
the increased activation attained with this condition was not much
greater than those seen with the non-stimulated control NIH3T3 lane.
ER/Golgi-Ras showed more potent MEK activation but was similarly
characterized by a profound inhibitory activity of the wild type variant
on MEK phosphorylation. Whilst wild type Ras is not constitutively
active we still found evidence of activation in our pull-downs (Fig. 2C).
One interpretation of our data is that with low levels of activation
more typical of normal Ras signaling, Golgi-Ras is able to engage path-
ways that negatively regulate MEK activity. An example could be RKTG
that sequesters Raf on to the Golgi and attenuates ERK activation [31].
With chronic Golgi-Ras stimulation this negative regulation is then lost
and/or there is speciﬁc recruitment and activation of the Raf-MAP kinase
cascade to the Golgi. Whilst we cannot discriminate between these
possibilities it is clear that Golgi-Ras plays an active role in modulating
MEK function.
A complex relationship is evident between Ras location, activation
state and Akt activation. In the presence of activated G12V N-Ras Akt
phosphorylation is reduced (Fig. 2B). This pattern is observed for Ras
targeted to all locations except ER/Golgi-Ras where the reverse is
true. Attenuated signaling in the presence of mutant Ras is seen in
cells with long-term expression due induction of negative feedback
mechanisms [32,33]. Therefore the observation of reduced Akt activa-
tion for constitutively active N-Ras and most of the other compartmen-
tal Ras proteins compared to wild type variants is not necessarily
unexpected. Importantly, Golgi-Ras follows a similar pattern to N-Ras.
Therefore analogous to the MEK data, whilst the G12V version appears
non-responsive compared to unstimulated control there is a clear inﬂu-
ence of Golgi-restricted Ras on Akt activation state when the wild type
version is considered. Taken together, we see that whilst MEK modula-
tion appears to be restricted to ER, Golgi and plasma membrane Ras, all
locations are able to inﬂuence Akt activation.
The ability of compartmental Ras to sustain a range of phenotypic
responses associated with normal Ras signaling was assayed. Measure-
ment of cell proliferation was inferred using an MTS cell viability assay.
All locationswere able to sustain equivalent Ras dependent levels of pro-
liferation to that seenwith activated N-Ras (Fig. 3A). Furthermore, in our
focus formation assays N-Ras, endo-Ras and Golgi-Ras generated signiﬁ-
cantly more foci than the GFP transfected control (Fig. 3B). Previous
analysis of compartmental Ras signaling found that KDELr(N193D)-Ras
localized to theGolgi displayed reduced proliferation and transformation
compared to Ras targeted to the ER and plasmamembrane [20]. One ex-
planation for the discrepancy in our results could be that the Golgi-Ras
used in the Matallanas study is impaired in its ability to cycle back to
the ER. A similar argumentwas posited for the lack of transforming activ-
ity of Golgi-Ras that contrasted with previous studies using non-mutant
KDELr as theGolgi targetingmotif [7,14,20]. Althoughwe cannot exclude
the possibility that the tiny fraction of Golgi-Ras that is resident on the
ER at steady state is solely responsible for our phenotypic observations
we note that similarly low levels of peripheral ER labeling were also
observed with KDELr(N193D)-Ras [20]. Furthermore, our Golgi-Rasconstruct exhibited more foci that the ER/Golgi-Ras arguing against a
predominant role for the ER in our phenotypic observations.
Finally, oncogenic Ras is able to provide resistance to pro-apoptotic
cisplatin-based chemotherapy in part via modulating MEK-ERK sig-
naling [34,35]. Whilst activated N-Ras, mito-Ras and endo-Ras exhibit
reduced apoptotic signaling as expected of normal Ras signaling, we in-
triguingly observed the opposite pattern for the Golgi and ER/Golgi-Ras
proteins (Fig. 3C). The protective effect of wt Golgi-Ras and ER/Golgi-Ras
correlates well with the minimal MEK activation observed with these
constructs and is consistent with the known requirement for MEK-ERK
signaling to mediate cisplatin-induced apoptosis in many cell types
[36,34,37].
3. Conclusions
Our study represents the ﬁrst comparative analysis across all loca-
tions where Ras isoforms are known to reside. Since Ras signaling
involves membrane resident components in addition to recruitment
of cytosolic factors we might expect that some locations would not
be competent for sustaining targeted Ras function. In fact we found
that Ras targeted to all locations was able to modulate signaling via
the canonical Ras pathways. This was accompanied by regulation of
phenotypic outputs including the ability for Golgi-Ras to promote
proliferation and transformation equivalent to that seen with N-Ras.
Whilst we cannot conﬁrm the extent to which these effects are directly
or indirectly mediated from each location our data highlight important
capacity for endomembranous Ras to modulate Ras outputs.
4. Materials and methods
4.1. Antibodies
Rabbit anti-phospho-Akt (Ser473), rabbit anti-phospho-MEK1/2
(Ser217/221), and mouse anti-cleaved PARP (Asp214) were all from
Cell Signaling Technology; mouse anti-tubulin (Sigma); mouse anti-
Tom20 (BD Biosciences); rabbit anti-GFP [38]; rabbit anti-EEA1 [39].
Sheep anti-Grasp55 antibody was a kind gift of Francis Barr.
4.2. Targeted Ras constructs
Wild type and activated (G12V) GFP-N-Ras, GFP-ER/Golgi-Ras
(GFP-N-HVR-Ala) and GFP-N-Ras acceptor constructs lacking the
C-terminal HVR have been previously described (Laude and Prior,
2008). The GFP-N-Ras acceptor constructs allow subcloning of mem-
brane targeting motifs C-terminal to the Ras G domain separated by a
three amino acid ARA-linker sequence. The following primers were
used to amplify the FENS1 FYVE domain (aa. 274–358), the GM130
Golgi targeting domain (aa 784–986) and the OMP25 mitochondrial
targeting domain (aa 170–206) from plasmids encoding the relevant
proteins: FENS_FYVE_F: 5′-ACTCGAGGTGAGCTCAGCAGAGAAGAGGC
TCCT-3′ and FENS_FYVE_R: 5′-CTCGAGGCCCCCACCGCCACGAGAAGT
CCGATCTTCATCTTTGATGGAGTC-3′. GM130_F: 5′-CTCGAGCTGCTCAC
TTGGCAGCCCCA-3′ and GM130_R: 5′-GAATTCTTATATAACCATGATTT
TCACCTCGTCGTTCTC-3′; OMP25_F: 5′-CTCGAGGACATCGAGGCGACG
GAGAGGCC-3′ and OMP25_R: 5′-GAATTCCCTCAGAGCTGCTTTCGGTA
TCTCACGAAGGC-3′. The sequenced targeting motifs were subcloned
into the N-Ras acceptor construct and correct targeting conﬁrmed in
HeLa cells by immunoﬂuorescence microscopy. HeLa cells were
grown at 37 °C in DMEM (Invitrogen) supplemented with 10% heat-
inactivated FBS. Cells were transfected with GeneJuice (Novagen)
according to the manufacturer's instructions.
4.3. Stable cell line generation
NIH3T3 FLP-IN cells (Invitrogen) were grown in the presence of
100 μg/ml Zeocin. For the stable expression of compartmentalized
Fig. 3. Phenotypic responses of compartmentalized Ras signaling. (A) Levels of cell proliferation normalized to NIH3T3 control. Mean values for percentage of proliferation are
shown. The described clones were seeded in triplicates on day 1 and cell numbers were determined 48 h post seeding by the MTS assay measuring absorbance at 490 nm (data
obtained from 6 independent experiments). (B) Effects of compartmentalized Ras on cellular transformation. NIH3T3 cells were transfected with 1 μg of each of activated organellar
Ras and cultured for 14 days in the presence of DMEM, 10% FBS containing 750 μg/ml G418. Foci were stained and the numbers of foci ≥2 mm diameter were counted; data rep-
resent means ± SEM of foci per well from three biological repeats. (C) Levels of cleaved PARP induced by cisplatin. NIH3T3 stably expressing the Ras targeted constructs were treat-
ed with 30 μM cisplatin for 24 h. PARP cleavage was monitored in 20 μg lysates by anti-cleaved PARP immunoblotting. This corresponds to a representative blot of three
independent experiments. Graph shows levels of cleaved PARP normalized to control.
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Organellar Ras constructs together with pOG44 as indicated by the
manufacturer's instructions. Transfections were performed using
TransIT-3T3 transfection kit (MirrusBio). After 48 h, exchange into
selection media (DMEM, 10% FBS, 200 μg/ml Hygromycin B) initiated
death of non-transfected cells. Clones derived from single cellswere pick-
ed and expanded and those positive for organellar Ras expression were
identiﬁed and veriﬁed using ﬂuorescence imaging and western blotting.4.4. Viability and cisplatin resistance assays
To measure proliferation, cells were cultured at a density of 2000
cells per well in 96-well plates. After 48 h, CellTiter 96 Aqueous One
Solution Reagent (Promega) was added to each well according to
the manufacturer's instructions. After 4 h in culture the cell viability
was determined by measuring the absorbance at 490 nm using a
Multiskan Spectrum plate reader (Thermo Labsystems). Values were
1753V. Aran, I.A. Prior / Cellular Signalling 25 (2013) 1748–1753converted from absorbance to cell number using a standard curve
prepared for each experiment. For cisplatin resistance measurements,
subconﬂuent cell cultures were incubated with 30 μM cisplatin
(cDDP; Sigma) for 24 h. Cells were lysed on ice using RIPA buffer
(10 mMTris-Cl pH 7.5, 150 mMNaCl, 1% Triton, 0.1% SDS, 1% sodium
deoxycholate) lysateswere separated by SDS–PAGE followed by immu-
noblotting, and ﬁnally analyzed with a LI-COR Odyssey 2.1 system.
4.5. Focus formation assay
NIH3T3 cells were plated in DMEM containing 10% FBS at a density
of 5 × 105 cells/60-mm plate. Sixteen hours later the cells were
transfected with 1 μg of each of activated organellar Ras and the fol-
lowing day media was exchanged for DMEM, 10% FBS containing
750 μg/ml G418. After 14 days the cells were ﬁxed with 0.2% glutaral-
dehyde, 0.5% formaldehyde in PBS for 10 min on ice and stained with
0.2% crystal violet for 10 min at room temperature. The number of
foci ≥2 mm diameter was counted; data represent means ± SEM of
foci per well from three biological repeats.
4.6. Ras activation assay
Conﬂuent organellar Ras NIH3T3 cells were washed with ice-cold
PBS and lysed on ice in 50 mM Tris-Cl (pH 7.2), 500 mM NaCl, 10 mM
MgCl2, 1% Triton X-100, 0.5% sodium deoxycholate and 1:250 protease-
inhibitor cocktail (Sigma). In order to afﬁnity-purify activated Ras from
200 μg of lysates, 11 μg of GST-RBD K85A fusion protein linked to
glutathione–Sepharose 4B was added to each lysate together with
at least a ﬁve-fold volume excess of binding buffer (50 mM Tris HCl,
pH 7.2, 10 mMMgCl2, 0.5 mg/ml bovine serum albumin (BSA), 0.5 mM
dithiothreitol and 150 mM NaCl) and incubated for 30 min at 4 °C.
Beads were washed twice in binding buffer (without BSA) before boiling
in SDS sample buffer for 10 min. Activated Ras in the pull-downs was
detected by western blotting with anti-GFP. GST-RBD K85A plasmid
was a gift from Dr Tony Burgess, Ludwig Institute, Melbourne, Australia
[40].
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